Developing an IFNγ-based molecular microscope to assess celiac disease activity and response to treatment without relying solely on diagnostic biopsies.
Mapping the full antigenic landscape of Sjögren's disease using T-Scan technology to identify the drivers of autoimmune T cell responses and enable targeted therapies.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.
Modernizing anti-nuclear antibody testing by combining AI-enhanced image analysis with multiplex autoantibody profiling to improve diagnostic precision and uncover novel autoimmune biomarkers.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Identifying urine DNA methylation signatures as a non-invasive biomarker for lupus nephritis class and disease progression.
Profiling immune responses in severe asthma patients before and after biologic treatment to identify biomarkers of response and novel drug targets.
